aTyr Pharma to Present at March Investor Conferences
08 mars 2023 08h00 HE
|
aTyr Pharma, Inc.
SAN DIEGO, March 08, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary...
Life & Banc Split Corp. Completes Treasury Offering
25 janv. 2023 08h47 HE
|
Life & Banc Split Corp.
Not for distribution to U.S. newswire services or for dissemination in the United States. TORONTO, Jan. 25, 2023 (GLOBE NEWSWIRE) -- (TSX: LBS, LBS.PR.A) Life & Banc Split Corp. (the...
aTyr Pharma Gains E.U. Patent Covering Use of Efzofitimod with Pirfenidone for Lung Inflammation or Fibrosis
19 janv. 2023 08h00 HE
|
aTyr Pharma, Inc.
SAN DIEGO, Jan. 19, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary...
Life & Banc Split Corp. Announces Successful Overnight Offering
18 janv. 2023 11h49 HE
|
Life & Banc Split Corp.
Not for distribution to U.S. newswire services or for dissemination in the United States. TORONTO, Jan. 18, 2023 (GLOBE NEWSWIRE) -- (TSX: LBS, LBS.PR.A) Life & Banc Split Corp. (the...
aTyr Pharma Announces LTBP1 as Target of DARS tRNA Synthetase Fragment
15 déc. 2022 08h00 HE
|
aTyr Pharma, Inc.
LTBP1 is key regulator of TGF-β, a major driver of fibrosis. Latest target identified from company’s platform in collaboration with Dualsystems Biotech AG. SAN DIEGO, Dec. 15, 2022 (GLOBE...
Life & Banc Split Corp. Establishes At-the-Market Equity Program
08 déc. 2022 09h54 HE
|
Life & Banc Split Corp.
Not for distribution to U.S. newswire services or for dissemination in the United States. TORONTO, Dec. 08, 2022 (GLOBE NEWSWIRE) -- (TSX: LBS, LBS.PR.A) Life & Banc Split Corp. (the...
Life Reinsurance Market Size In 2022 (New Report) | No. of pages: 115|: Manufacturers Data, Opportunity, Import Export Scenario, Application, Type, Regions and Future Forecast till 2028 with Top Growth Companies
16 nov. 2022 02h12 HE
|
Proficient Market Insights
Pune, Nov. 16, 2022 (GLOBE NEWSWIRE) -- "Life Reinsurance Market" research report focus on overall information that can help to take decisions on current market situation. Reinsurance, also known as...
aTyr Pharma Announces Third Quarter 2022 Results and Provides Corporate Update
10 nov. 2022 16h00 HE
|
aTyr Pharma, Inc.
First patient dosed in Phase 3 EFZO-FIT™ study in patients with pulmonary sarcoidosis; multiple centers in the U.S. are open for enrollment. Company to prioritize resources towards largest value...
aTyr Pharma to Present at Upcoming Investor Conferences
10 nov. 2022 08h00 HE
|
aTyr Pharma, Inc.
SAN DIEGO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary...
aTyr Pharma Announces Publication of Positive Data from Phase 1b/2a Clinical Study of Efzofitimod for the Treatment of Pulmonary Sarcoidosis in the Journal CHEST
09 nov. 2022 08h00 HE
|
aTyr Pharma, Inc.
First therapy in sarcoidosis to reduce steroid burden while demonstrating improvements in key physiologic and quality of life measures. Global pivotal Phase 3 EFZO-FIT™ study currently enrolling. ...